Although TET-2 mutations are considered secondary events in nMTCL-TFH-phenotype, different studies demonstrate an association of TET-2 and RhoA G17V mutations in these neoplasms, suggesting a biological cooperation between both mutations to promote AITL development (49, 65). The gene discussed is TET2; the disease is angioimmunoblastic T-cell lymphoma.